January 31, 2022
  • Last week, AHIP submitted comments reflecting the group’s concerns with provisions in the HHS Notice of Benefit and Payment Parameters for 2023. AHIP warned that proposed requirement for insurers to offer standardized plan options on the exchanges would “stifle innovation” and includes provisions that would be hard for payers to roll out, such as common drug formulary designs. The group also stated the potential changes to requirements for essential health benefits would limit the ability for insurers to manage costs, particularly for prescription drugs, and manage chronic illnesses. (Press release here)